Abstract: Provided is a compound having anti-tumor activity and a use thereof. As a PRMT5 inhibitor, the compound has a structure represented by formula (I). Experiments have confirmed that these compounds have strong inhibitory effects on PRMT5 enzyme activity and tumor cell growth, and can be used as promising compounds for treating PRMT5-mediated diseases. Furthermore, a specific synthesis method is further studied. The synthesis method is simple in process, convenient to operate, and beneficial to large-scale industrial production and application.

Abstract: The invention provides a class of compounds represented by Formula (I), and pharmaceutically acceptable salts thereof. The compounds of the invention have strong inhibitory activity against Lp(a) assembly and can be used to treat cardiovascular diseases (CVDs).

Abstract: Aromatic heterocyclic compounds as ENPP1 inhibitors, a preparation method therefor and the uses thereof. The compounds have structures as shown in formula (I).

Abstract: An anti-misplug detection mechanism may include: a plurality of first communication interfaces, and anti-misplug detection assemblies. The plurality of first communication interfaces may be used to be mutually plug-in connected to second communication interfaces on the code scanners one to one to form a plurality of code scanner plug-in assembly groups; and the anti-misplug detection assemblies may be arranged in groups with the first communication interfaces, and include a first matching structure, a second matching structure and a detector. The first matching structures and the first communication interfaces may be relatively fixed one to one, the second matching structures may be connected to the code scanners one to one through connecting elements, and a first mistake-proofing feature and a second mistake-proofing feature of the same group may be matched with each other.

Abstract: Disclosed are a class of compounds having a new structure as an ATR inhibitor, and a stereoisomer, an optical isomer, a pharmaceutical salt, a prodrug and a solvate thereof. An in-vitro enzyme inhibitory activity study shows that the compounds have a strong inhibitory effect on an ATR enzyme, and can be used as prospecting compounds for treating ATR-mediated diseases.

Abstract: A compound represented by formula (I), or a stereoisomer, a tautomer, an isotope-labeled form, a nitrogen oxide, a solvate, a polymorph, a pharmaceutically acceptable salt, or a prodrug thereof, a method for preparing the same, and a pharmaceutical composition comprising the same are provided. The compound is a NK-3 receptor antagonist, and may be used for preventing and/or treating depression, anxiety disorder, psychosis, schizophrenia, psychotic disorder, bipolar disorder, cognitive disorder, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, convulsion, obesity, inflammatory disease, vomiting, preeclampsia, airway-related disease, reproductive disorder, contraception and sex hormone-dependent disease, gynecological disease-related disease, or menopausal syndrome-related disease.

Abstract: A compound of Formula I, or a racemate, a racemate, a stereoisomer, a tautomer, an isotopically labeled compound, an N-oxide, a solvate, a polymorph, a metabolite, an ester, a prodrug or a pharmaceutically acceptable salt thereof are provided. Also provided is a pharmaceutical composition containing the compound of Formula I and derivatives, a preparation method therefor, and use thereof as a GHSR agonist in the preparation of drugs for diagnosing, preventing and/or treating growth hormone dependent disease.

Abstract: An anti-misplug detection mechanism may include: a plurality of first communication interfaces, and anti-misplug detection assemblies. The plurality of first communication interfaces may be used to be mutually plug-in connected to second communication interfaces on the code scanners one to one to form a plurality of code scanner plug-in assembly groups; and the anti-misplug detection assemblies may be arranged in groups with the first communication interfaces, and include a first matching structure, a second matching structure and a detector. The first matching structures and the first communication interfaces may be relatively fixed one to one, the second matching structures may be connected to the code scanners one to one through connecting elements, and a first mistake-proofing feature and a second mistake-proofing feature of the same group may be matched with each other.

Abstract: A compound, as represented by formula I, as a TLR7 agonist, a method for preparing the compound, and the use of the compound in treating diseases mediated by the TLR7 agonist are provided. Studies on the activity of a human-derived receptor, a TLR7 agonist, show that compounds have a strong agonistic effect on the human-derived receptor, TLR7, and can be used as a foreground compound for treating diseases mediated by the TLR7 agonist.

Abstract: The disclosure relates to the technical field of detection devices, and provides a carved code quality detection apparatus and system, wherein the carved code quality detection apparatus includes: a support assembly, including a guide rod, a baffle and a first support plate, the guide rod extending along the height direction, the baffle being fixedly connected to the upper end of the guide rod, and the first support plate being fixedly connected to the lower end of the guide rod; a visual detection system, including an imaging assembly movably connected to the guide rod; and a driving assembly, arranged on the baffle and connected to the imaging assembly, the driving assembly being configured to drive the imaging assembly. The technical solutions can achieve online detection of the carved code quality of a member to be detected, thereby reducing the risk of false detection or missed detection caused by manual visual inspection.

Abstract: The present invention relates to the field of medical technology, and in particular, to a variety of substituted N-(5-(quinolin-6-yl)pyridin-3-yl) benzsulfamide derivatives represented by formula (1) (groups therein are as defined in the specification). The compounds according to the present invention have favorable anti-tumor activity against human lung cancer, colon cancer, liver cancer, breast cancer and glioblastoma multiforme, which contribute to development of highly effective, low toxic and high specific anti-tumor drugs, and have high value of development. The present invention also relates to a composition, preparation method and use thereof in the preparation of anti-tumor drugs.

Abstract: Described herein are substituted norindenoisoquinoline compounds, and pharmaceutical compositions and formulations comprising the norindenoisoquinoline compounds. Also described herein are methods for using the compounds for the treatment and/or prevention of topoisomerase mediated diseases, such as cancer.

Abstract: An indenoquinolone compounds of Formula (A) is disclosed, wherein the definition of each group is described in the description. These compounds may specifically inhibit topoisomerase I, and they have good activities against many kinds of human tumor cells, such as lung cancer, colon cancer, breast cancer, liver cancer and the like. They can be used in the manufacture of antitumor drugs. The method for preparing the compound of formula (A), and pharmaceutical compositions containing such compounds and the use in the manufacture of antitumor drugs are also disclosed.

Abstract: The present invention relates to the field of medical technology, and in particular relates to a kind of gemcitabine amide derivative with a novel structure. The new compounds of the present invention are very active with regard to many tumour cells such as human lung cancer, colon cancer, breast cancer and liver cancer etc., and therefore can be used for preparing anti-tumour drugs. In addition, these compounds also have anti-viral activity. Also disclosed are a preparation method for the compounds, a pharmaceutical composition containing the compounds and the use thereof in preparing drugs against tumours and viruses etc.

Abstract: An indenoquinolone compounds of Formula (A) is disclosed, wherein the definition of each group is described in the description. These compounds may specifically inhibit topoisomerase I, and they have good activities against many kinds of human tumor cells, such as lung cancer, colon cancer, breast cancer, liver cancer and the like. They can be used in the manufacture of antitumor drugs. The method for preparing the compound of formula (A), and pharmaceutical compositions containing such compounds and the use in the manufacture of antitumor drugs are also disclosed.

Abstract: Described herein are substituted norindenoisoquinoline compounds, and pharmaceutical compositions and formulations comprising the norindenoisoquinoline compounds. Also described herein are methods for using the compounds for the treatment and/or prevention of topoisomerase mediated diseases, such as cancer.